Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant Monitoring
SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will be presenting the latest information on its AlloSeq® portfolio of pre- and post-transplant solutions for human leukocyte antigen (HLA) typing, including QTYPE®, and post-transplant hematopoietic stem cell and organ transplant surveillance during poster presentations and the symposium taking place at this year’s EFI 2022 Conference. Read the complete press release on CareDx.com.